Five Prime Therapeutics Licenses Antibodies to Seattle Genetics for Use in Novel ADC Programs
Five Prime Therapeutics, Inc. announced a global license agreement with Seattle Genetics, Inc. to develop and commercialize novel antibody-drug conjugate (ADC) therapies using…
Read More...
Read More...
